Biogen (NASDAQ:BIIB) Upgraded by Argus to "Hold" Rating

Key Points

• Argus upgraded Biogen to a “Hold” rating; across analysts the stock has 12 Buys, 15 Holds and 1 Sell, yielding an overall average rating of "Hold" and an average price target of $207.92.
• Biogen beat the quarter with EPS of $1.99 vs. $1.61 consensus and revenue of $2.28B, though revenue was down 7.2% year‑over‑year, and management set FY2026 guidance of 15.25–16.25 EPS (analysts expect 15.83).
• The stock opened at $172.97 (market cap $25.38B), trading below its 50‑day moving average ($186.59) but near its 200‑day average ($172.47), with a 12‑month range of $112.18–$202.41.

Biogen (NASDAQ:BIIB - Get Free Report) was upgraded by equities research analysts at Argus to a "hold" rating in a research note issued to investors on Thursday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Biogen in a research report on Monday, February 9th. Oppenheimer upped their price target on Biogen from $250.00 to $275.00 and gave the stock an "outperform" rating in a report on Wednesday, April 1st. HSBC upped their price target on Biogen from $143.00 to $150.00 and gave the stock a "reduce" rating in a report on Tuesday, March 17th. Piper Sandler upped their price target on Biogen from $157.00 to $177.00 and gave the stock a "neutral" rating in a report on Monday, February 9th. Finally, Wedbush upped their price target on Biogen from $187.00 to $191.00 and gave the stock a "neutral" rating in a report on Wednesday, April 1st. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Biogen has an average rating of "Hold" and an average price target of $207.92.

Biogen Stock Down 2.3%

Shares of Biogen stock opened at $172.97 on Thursday. The stock has a market capitalization of $25.38 billion, a P/E ratio of 19.63, a PEG ratio of 2.36 and a beta of 0.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a 50 day moving average price of $186.59 and a two-hundred day moving average price of $172.47. Biogen has a 12-month low of $112.18 and a 12-month high of $202.41.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analysts' expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company's revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts expect that Biogen will post 15.83 earnings per share for the current year.

Insider Activity at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Convergence Investment Partners LLC acquired a new position in Biogen during the third quarter worth $1,342,000. Caprock Group LLC acquired a new position in Biogen during the third quarter worth $742,000. Pitcairn Co. acquired a new position in Biogen during the second quarter worth $936,000. Fluent Financial LLC acquired a new position in Biogen during the third quarter worth $3,578,000. Finally, Leuthold Group LLC acquired a new position in Biogen during the third quarter worth $3,294,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.